Outlook Therapeutics launches public offering with accompanying stock purchase warrants - OTLK News | RalliesOutlook Therapeutics launches public offering with accompanying stock purchase warrants
O
OTLK• Public offering and warrants
- Outlook Therapeutics launched an underwritten public offering of common stock with accompanying warrants to buy common shares.
- Underwriters received a 30-day option to purchase up to 15% more shares and/or accompanying warrants on the same terms.
- Net proceeds are earmarked for the U.S. commercial launch of LYTENAVA, working capital, and general corporate purposes.
- The offering was made under an effective shelf registration statement on Form S-3 filed March 28, 2024, and effective April 5, 2024.
